Probiodrug, the Germany-based developer of small molecule inhibitors against inflammatory and neurodegenerative diseases, has raised €20.6m in series A funding from Bayern Kapital (Seedfonds Bayern), HBM Biopartners, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, Sachsen LB Corporate Finance Holding GmbH (Dresden Fonds GmbH), TVM Capital GmbH, tbg Technologie-Beteiligungs-Gesellschaft and Georg Frank. Probiodrug is developing a new approach to treating Alzheimer’s disease and other neurodegenerative and inflammatory diseases, focusing on the enzyme glutaminyl cyclase. The funding will allow Probiodrug to advance preclinical and clinical development of its small molecule drugs. The company simultaneously announced the acquisition of Germany-based Ingenium Pharmaceuticals, a discovery and development company focused on inflammatory diseases.

PregLem, the Switzerland-based specialty biopharmaceutical company, has raised €20m in series A funding from Sofinnova Partners, MVM and Neomed Management. PregLem also announced the signing of a licensing agreement with Euronext-listed Ipsen, under which Ipsen will grant PregLem worldwide development and commercialisation rights to certain Ipsen compounds, for use in reproductive medicine only. The funding will allow PregLem to undertake the development of these and other key compounds in the PregLem portfolio.

Kiadis, the Netherlands-based oncology product development company, has raised €15m from Alta Partners, Esprit Capital, Life Sciences Partners, MedSciences Capital, N.V. NOM and Quest for Growth. The Kiadis product pipeline is focused on providing novel treatments in the field of bone marrow transplants and the treatment of aggressive cancers. The four most advanced products are currently in clinical trials, ranging from phase I to entering phase III.

For a summary of the week's news across the entire venture-backed private market subscribe to Library House's free VentureCast Newsletter.